Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

1.

The impact on the multidisciplinary team of molecular profiling for personalized therapy in non-small cell lung cancer.

Blackhall F, Thatcher N, Booton R, Kerr K.

Lung Cancer. 2013 Feb;79(2):101-3. doi: 10.1016/j.lungcan.2012.10.016. Epub 2012 Nov 22. Review.

PMID:
23182148
[PubMed - indexed for MEDLINE]
2.

Personalized therapy for non-small cell lung cancer: which drug for which patient?

Villaruz LC, Socinski MA.

Semin Thorac Cardiovasc Surg. 2011 Winter;23(4):281-90. doi: 10.1053/j.semtcvs.2012.01.001. Review.

PMID:
22443647
[PubMed - indexed for MEDLINE]
3.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

PMID:
22457323
[PubMed - indexed for MEDLINE]
Free Article
4.

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA.

J Clin Oncol. 2010 Nov 1;28(31):4769-77. doi: 10.1200/JCO.2009.27.4365. Epub 2010 Oct 4. Review.

PMID:
20921461
[PubMed - indexed for MEDLINE]
5.

Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.

Ou SH.

Drug Des Devel Ther. 2011;5:471-85. doi: 10.2147/DDDT.S19045. Epub 2011 Nov 23. Review.

PMID:
22162641
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.

Pilotto S, Peretti U, Novello S, Rossi G, Milella M, Giaj Levra M, Ciuffreda L, Massari F, Brunelli M, Tortora G, Bria E.

Expert Opin Pharmacother. 2013 Apr;14(5):597-608. doi: 10.1517/14656566.2013.778828. Epub 2013 Mar 9. Review.

PMID:
23472711
[PubMed - indexed for MEDLINE]
7.

Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach.

Salto-Tellez M, Tsao MS, Shih JY, Thongprasert S, Lu S, Chang GC, Au JS, Chou TY, Lee JS, Shi YK, Radzi A, Kang JH, Kim SW, Tan SY, Yang JC.

J Thorac Oncol. 2011 Oct;6(10):1663-9. doi: 10.1097/JTO.0b013e318227816a.

PMID:
21869714
[PubMed - indexed for MEDLINE]
8.

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.

Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, Milton DT, Strawn JR, Wakelee HA, Giaccone G.

J Clin Oncol. 2011 May 20;29(15):2121-7. doi: 10.1200/JCO.2010.31.8923. Epub 2011 Apr 11.

PMID:
21482992
[PubMed - indexed for MEDLINE]
9.

Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.

Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T.

Lung Cancer. 2011 Mar;71(3):249-57. doi: 10.1016/j.lungcan.2010.12.008. Epub 2011 Jan 8. Review.

PMID:
21216486
[PubMed - indexed for MEDLINE]
10.

Treatment of ALK-positive non-small cell lung cancer.

Bang YJ.

Arch Pathol Lab Med. 2012 Oct;136(10):1201-4.

PMID:
23020724
[PubMed - indexed for MEDLINE]
11.

Personalized medicine for non-small-cell lung cancer.

Mok TS, Zhou Q, Leung L, Loong HH.

Expert Rev Anticancer Ther. 2010 Oct;10(10):1601-11. doi: 10.1586/era.10.76. Review.

PMID:
20942631
[PubMed - indexed for MEDLINE]
12.

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, Camidge DR.

Lancet Oncol. 2011 Oct;12(11):1004-12. doi: 10.1016/S1470-2045(11)70232-7. Epub 2011 Sep 18.

PMID:
21933749
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.

Shukuya T, Takahashi T, Kaira R, Ono A, Nakamura Y, Tsuya A, Kenmotsu H, Naito T, Kaira K, Murakami H, Endo M, Takahashi K, Yamamoto N.

Cancer Sci. 2011 May;102(5):1032-7. doi: 10.1111/j.1349-7006.2011.01887.x. Epub 2011 Feb 28.

PMID:
21272159
[PubMed - indexed for MEDLINE]
14.

Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.

Lee JO, Kim TM, Lee SH, Kim DW, Kim S, Jeon YK, Chung DH, Kim WH, Kim YT, Yang SC, Kim YW, Heo DS, Bang YJ.

J Thorac Oncol. 2011 Sep;6(9):1474-80. doi: 10.1097/JTO.0b013e3182208fc2.

PMID:
21642865
[PubMed - indexed for MEDLINE]
15.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938
[PubMed - indexed for MEDLINE]
16.

The role of molecular analyses in the era of personalized therapy for advanced NSCLC.

Tanner NT, Pastis NJ, Sherman C, Simon GR, Lewin D, Silvestri GA.

Lung Cancer. 2012 May;76(2):131-7. doi: 10.1016/j.lungcan.2011.11.013. Epub 2011 Dec 15. Review.

PMID:
22176813
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.

N Engl J Med. 2004 May 20;350(21):2129-39. Epub 2004 Apr 29.

PMID:
15118073
[PubMed - indexed for MEDLINE]
Free Article
18.

Personalized targeted therapy in advanced non-small cell lung cancer.

Ma PC.

Cleve Clin J Med. 2012 May;79 Electronic Suppl 1:eS56-60. doi: 10.3949/ccjm.79.s2.12. Review.

PMID:
22614968
[PubMed - indexed for MEDLINE]
Free Article
19.

Molecular oncology of lung cancer.

Toyooka S, Mitsudomi T, Soh J, Aokage K, Yamane M, Oto T, Kiura K, Miyoshi S.

Gen Thorac Cardiovasc Surg. 2011 Aug;59(8):527-37. doi: 10.1007/s11748-010-0743-3. Epub 2011 Aug 18. Review.

PMID:
21850578
[PubMed - indexed for MEDLINE]
20.

Reflex testing for epidermal growth factor receptor mutation and anaplastic lymphoma kinase fluorescence in situ hybridization in non-small cell lung cancer.

Mino-Kenudson M, Mark EJ.

Arch Pathol Lab Med. 2011 May;135(5):655-64. doi: 10.1043/2011-0029-RAI.1. Review.

PMID:
21526964
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk